NCT00964457

Brief Summary

response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Aug 2009

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2009

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

August 21, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 25, 2009

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

August 25, 2009

Status Verified

August 1, 2009

Enrollment Period

2.9 years

First QC Date

August 21, 2009

Last Update Submit

August 24, 2009

Conditions

Keywords

cetuximabrectum cancerradiationMRI

Outcome Measures

Primary Outcomes (1)

  • response rate

    3 years

Study Arms (2)

Capecitabine, oxaliplatin

ACTIVE COMPARATOR
Drug: cetuximab

capecitabine, oxaliplatin and cetuximab

ACTIVE COMPARATOR

capecitabine, oxaliplatin ane cetuximab

Drug: cetuximab

Interventions

cetuximab 500mg per meter square every second week

Capecitabine, oxaliplatincapecitabine, oxaliplatin and cetuximab

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • advanced rectum cancer

You may not qualify if:

  • prior radiation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Herlev Hospital

Herlev, 2730, Denmark

Location

MeSH Terms

Conditions

Rectal Neoplasms

Interventions

Cetuximab

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 21, 2009

First Posted

August 25, 2009

Study Start

August 1, 2009

Primary Completion

July 1, 2012

Study Completion

July 1, 2017

Last Updated

August 25, 2009

Record last verified: 2009-08

Locations